New longevity drug for dogs could extend your pet's life — and pave the way for humans to live longer too
Sit, stay… live longer?
Research shows that owning a dog can help humans live longer, healthier lives. Now, a US biotech company wants to return the favor with anti-aging drugs designed to extend the lifespan of your canine companion.
'The longevity space is crowded right now, and for good reason,' Celine Halioua, founder and CEO of Loyal, told The Post. 'We all want to figure out how to get more happy, healthy years for our loved ones —especially the furry ones.'
6 Celine Halioua is leading the push to develop drugs that extend the lives of dogs.
X/@loyalfordogs
Before launching Loyal in 2019, Halioua worked on treatments for neurodegenerative diseases in humans — conditions that, much like aging in dogs, have no true preventive medicine.
'This combination of experience sparked my mission to develop the first drug approved for healthy lifespan extension,' she said.
Good boys, great science
Loyal has three longevity drugs in the pipeline, including two that specifically target bigger breeds, which typically have much shorter lifespans.
While small dogs like Chihuahuas can live for 18 years or longer, giant breeds such as Great Danes would be lucky to make it to ten.
That's where LOY-001 and LOY-003 come in. These drugs target dogs age seven and older that weigh at least 40 pounds.
6 Loyal's drugs aim to increase and quality of life for senior dogs.
X/Celine Halioua
They work by reducing levels of insulin-like growth factor 1 (IGF-1), a hormone that fuels cell growth. Scientists believe that high levels of IGF-1 shorten the lifespan of large dogs, which can have up to 28 times more of the hormone than smaller breeds.
One version, LOY-001, is an injectable given a few times a year at the vet. The other, LOY-003, is a daily chewable pill.
Both drugs are currently in pilot studies, and Loyal is eyeing conditional FDA approval by 2027.
Loyal's third longevity drug, LOY-002, is even further along in development. The treatment targets senior dogs age 10 and up that weigh at least 14 pounds.
It's currently being tested in a large-scale clinical trial involving more than 1,200 dogs across 70 clinics, making it one of the biggest studies in veterinary history, according to Halioua.
6 Small dogs tend to have a longer lifespan than larger breeds.
X/Celine Halioua
The drug works by targeting metabolism — the complex system of chemical reactions that powers essential functions like breaking down food, producing energy and repairing cells.
As metabolism slows with age, it can lead to insulin resistance and trigger a range of health issues in both humans and dogs, including cognitive decline, osteoarthritis and cancer.
'Improving metabolic health is one of the most well-validated pathways for extending both lifespan and healthspan,' Halioua said.
'Research [shows] it can improve health and reduce the risk of age-related diseases across species — from mice to humans,' she added.
So far, things are looking paws-itive. A pilot study of 48 dogs showed no adverse effects after three months of LOY‑002.
6 Both LOY-002 and LOY-003 are administered via a daily pill.
X/Celine Halioua
Loyal previously told The Guardian it's hoping the drug could add at least one extra year to a dog's life — and they'll be healthier during that time, too.
Once it's approved, Halioua hopes LOY‑002 will become a common preventive tool, like flea and tick medication.
'We expect all dogs to benefit from its ability to protect against, and even reverse, some of the harmful effects of metabolic dysfunction,' she said.
Loyal anticipates that the drug will receive conditional approval by the FDA in 2026.
6 Loyal is aiming to enroll 1,300 dogs in it's LOY-002 study.
X/Celine Halioua
But the dogs aren't the only ones who could benefit.
'We're on track to develop the first-ever FDA-approved drug for longevity — for any species,' Halioua said.
'Dogs share our environments and develop remarkably similar age-related diseases at similar stages of life, making them valuable models for human health and scientific research,' she added.
Dogs make us healthier, too
Halioua's lifelong love of animals runs deep.
'I've always been surrounded by animals — growing up, my family had 15 pets and rehabilitated wild animals,' she said. 'My Rottweiler, Della, is always by my side and is a major influence on the work I do.'
It turns out dogs don't just bring love — they could bring health benefits as well.
Studies show that dogs can ease loneliness, stress and anxiety. One even found that just 10 minutes of petting a pooch can significantly reduce levels of cortisol, the body's main stress hormone.
6 Dogs are known for their unconditional love and companionship.
yurakrasil – stock.adobe.com
Even locking eyes with your dog gives your brain a boost. A 2009 Japanese study found that staring into their eyes raises oxytocin — the 'love hormone' linked to bonding and happiness.
Dogs might even help you live longer. A sweeping review of research from 1950 to 2019 found that dog owners consistently have a lower risk of death compared to those without pets.
It's no accident. Research shows that dog owners tend to have lower blood pressure, cholesterol and a reduced risk of heart disease. Plus, they get more exercise, which builds muscle, strengthen bones and joints and keeps weight in check.
That's no coincidence. Dog owners tend to have lower blood pressure, cholesterol, and less risk of heart disease. Plus, they're more active — walking their dogs regularly strengthens muscles, bones and joints, and helps keep weight in check.
Some research even links dog ownership to bigger brains and sharper thinking, with faster processing speed and better memory.
And here's the kicker: a major study found owning a dog lowers dementia risk — a benefit not shared by cat owners.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
3 hours ago
- The Hill
Thanks to imported drugs, America has lost control of its medicine cabinet
America is facing a growing crisis in its medical system — not from a lack of talent or innovation, but from a breakdown in the control, safety and supply of essential medicines. Our growing reliance on imports is now driving serious drug shortages, destabilizing supply chains and increasingly making medications unsafe. At the root of it is a hard truth: We no longer have control of the medicines we depend on every day. In 2002, America manufactured 83.7 percent of the pharmaceuticals it consumed. By 2024, that number had dropped to just 37.1 percent. Meanwhile, the U.S. pharmaceutical trade deficit has soared, reaching a record $118.3 billion in 2024. We didn't just outsource manufacturing — we outsourced the sovereignty and safety of our health care system. This means that nearly two-thirds of America's pharmaceutical supplies are now imported. Most critical medications, such as generic drugs, now come from China and India. China controls 80 to 90 percent of the global supply of active pharmaceutical ingredients — the chemical building blocks of modern medicine. Even drugs labeled 'Made in the USA' often chemically originate in China. And India, which produces about half of America's finished generic drugs, relies on China for up to 80 percent of its active pharmaceutical not a supply chain — it's a ticking time something goes wrong, American patients suffer. In 2023, the Food and Drug Administration shut down a single Indian plant responsible for 50 percent of the U.S. supply of cisplatin, a critical chemotherapy drug, after uncovering a 'cascade of failure' in safety practices and shredded documents soaked in acid. With no domestic backup, patients nationwide had their treatments delayed. That wasn't a fluke. 40 percent of U.S. generic drugs have only one FDA-approved manufacturer. Because of that single chokepoint, when one factory fails, the whole system can crack. We are now seeing widespread drug shortages across the medical system. Hospital pharmacists report an average of 301 critical drug shortages at any given time. And 85 percent say these shortages are moderately or critically affecting care. Doctors often lack crucial medicines such as antibiotics, sedatives and cancer drugs. These aren't obscure drugs. They're foundational medicines. But America no longer makes them. Even when imported drugs do arrive, they're not always safe. A 2025 study found that Indian generics are 54 percent more likely to cause serious side effects than their U.S.-made counterparts. Indian factory violations have also been tied to at least eight U.S. patient deaths. China's record is equally disturbing. In 2008, dozens of Americans died after receiving contaminated heparin from Chinese suppliers. This isn't what the American people want. In a national survey, 85 percent of hospital pharmacists said they would pay more for safer generics. But under today's rules, price overshadows quality. Hospitals have little oversight of drug quality — and foreign producers face few consequences for cutting corners. Even the federal government is flying blind. A 2023 Department of Defense review found that 22 percent of essential military-use drugs had unknown ingredient sourcing. That's a national security April, the Trump administration took a necessary step by launching an investigation into generic pharmaceutical imports that correctly frames the issue as a national security threat. But that recognition alone isn't enough. To address this crisis, Washington should impose targeted tariffs on generic drugs from adversarial nations. It must also rebuild domestic pharmaceutical production through tax credits and long-term contracts. America urgently needs full transparency in drug labeling to disclose where drugs and their ingredients are made. The FDA must step up — with stronger enforcement abroad and a ban on imports from repeat safety violators. And to secure critical ingredients during market disruptions, Washington must pursue a long-term vision that includes a 'strategic pharmaceutical reserve.' This isn't just protectionism. It's a restoration of America's medical security. No nation can call itself sovereign if it can't produce its own medicines, and no patient is safe if their health care depends on quality control in a factory 8,000 miles decades, we were told that offshoring production would make things cheaper, smoother and more efficient. But America can no longer depend on unstable foreign suppliers. It's time to restore our pharmaceutical independence and take back control of our medicine cabinet. Andrew Rechenberg is an economist at the Coalition for a Prosperous America.
Yahoo
3 hours ago
- Yahoo
FDA-Approved Sleeping Pill Slows Alzheimer's Tangles in Pre-Clinical Trial
A drug used to treat insomnia has protected mice against the buildup of the tau protein found to clump abnormally in neurodegenerative diseases like Alzheimer's. This could lead to new ways to help slow the progress of these diseases. An increasing number of people are facing cognitive decline personally or in their loved ones. There are almost 10 million new cases of dementia globally each year, and despite decades of research, there are still few treatment options that provide clear benefits. So due to the links between Alzheimer's and poor sleep, Washington University neurologist Samira Parhizkar and colleagues investigated a central nervous system depressant, lemborexant, that was approved for use as a sleep aid by the FDA in December 2019. "We have shown that lemborexant improves sleep and reduces abnormal tau, which appears to be a main driver of the neurological damage that we see in Alzheimer's and several related disorders," explains Washington University neurologist David Holtzman. The role of amyloid beta proteins in Alzheimer's has been controversial, but they're not the only proteins implicated in the disease. Tau proteins normally contribute to the structure of brain cells, but past research has linked abnormal ones with the rate of brain atrophy in animal models. "The antibodies to amyloid that we now use to treat patients with early, mild Alzheimer's dementia are helpful, but they don't slow the disease down as much as we would like," says Holtzman. "We need ways to reduce the abnormal tau buildup and its accompanying inflammation, and this type of sleep aid is worth looking at further." But when the researchers compared lemborexant with another sleep aid, zolpidem, the results were unexpected. Mice receiving lemborexant retained up to 40 percent more volume in their memory-forming hippocampus than those who received zolpidem or no sleep aid at all. "What was surprising was that these effects were not seen with a standard sleep drug like zolpidem, which increases NREM sleep similarly to lemborexant," Parhizkar told Eric Dolan at PsyPost. "This suggests that the benefit is not just about more sleep, but rather how that sleep is promoted." The two sleep drugs work on different mechanisms, and that seems to be key to the protective effects. Lemborexant blocks orexin, a neuropeptide that regulates the sleep cycle, and when the team genetically knocked out orexin receptor 2 in mice, it reduced the buildup of tau in their brains. Strangely, though, the protective results of lemborexant were only seen in male mice, even though females were also tested. What's more, mouse studies don't always produce the same results in humans. Lemborexant has only been approved for short-term use in humans, so its long-term impacts as well as effectiveness in tau reduction still need to be investigated. While many questions remain to be answered, if the results seen in this study hold true, the researchers hope early intervention with a drug like lemborexant could potentially delay the progression of neurodegeneration. This research was published in Nature Neuroscience. Risk of Sleep Breathing Disorder Set to Rise 45% by End of Century Breakthrough: FDA Approves Injection to Prevent HIV Is It Gastro or Food Poisoning? Here's A Guide to Your Upset Stomach
Forbes
4 hours ago
- Forbes
CDC Vaccine Advisors To Vote On Thimerosal In Flu Shots. Here's What To Know About Thimerosal
ATLANTA, GA - OCTOBER 05: A podium with the logo for the Centers for Disease Control and Prevention ... More at the Tom Harkin Global Communications Center on October 5, 2014 in Atlanta, Georgia. (Photo by Kevin C. Cox/Getty Images) The CDC's Advisory Committee on Immunization Practices is set to vote later this week on the issue of thimerosal in flu vaccines. What exactly is thimerosal and is it actually harmful for people that take vaccines containing the substance? Thimerosal is a mercury-based organic preservative that historically was put in several vaccines in low quantities in order to prevent the growth of harmful bacteria and fungi, particularly when multi-dose vials were used. Vaccines can become accidentally contaminated, as may occur with multiple needle punctures with multi-dose vials. Before the late 1990's, infants were recommended to receive three vaccines that contained thimerosal- hepatitis B, Haemophilus influenzae type b and diphtheria-tetanus-acellular pertussis. There are no known health risks associated with thimerosal at the concentrations used in vaccines, according to the FDA. Secretary of Health and Human Services Robert F. Kennedy Jr. disagrees. In his 2014 book, he states (as reported in Politico), 'there is a virtually unanimous scientific consensus among the hundreds of research scientists who have published peer-reviewed articles in the field that Thimerosal is immensely toxic to brain tissue.' Thimerosal, as a preservative gets metabolized as ethylmercury, which is distinct from the more toxic methylmercury. In large doses, both compounds can be toxic to the brain and kidney, resulting in tremors, memory loss, mood swings, depression, protein in the urine and kidney damage. However, ethylmercury poses a significantly decreased risk for humans because it has a much shorter half-life of less than week compared to methylmercury, which has a half-life of 1.5 months according to the World Health Organization. Ethylmercury is removed from the body fast and actively excreted into the gut, as oppose to methylmercury that can accumulate in the body and result in potential toxic effects. In 1999, because of scientific uncertainty at the time and theoretical concerns about thimerosal, the preservative was removed from nearly all childhood vaccines as a precautionary measure per the FDA, not because it was shown to cause any harm. The only childhood vaccine that still contains thimerosal in some formulations is the flu vaccine. Part of the reason thimerosal was removed from childhood vaccines was because an infant in the early 1990s receiving childhood vaccines could be exposed to a cumulative dose of mercury as high as 187.5 micrograms by the age of 6 months, which exceeded the guidelines put forth by the EPA, but not the WHO. Even at a dose of 187.5 micrograms of ethylmercury, no studies have shown adverse health effects or harm to humans, other than local skin reactions at the injection site of the vaccine, as shown in a study published in the journal Pediatrics. Despite what Secretary of HHS Kennedy has suggested, thimerosal has not been shown to cause autism. In fact both the FDA and multiple peer-reviewed scientific studies have asserted and shown no link between thimerosal use in vaccines and autism. The use of thimerosal in U.S. FDA licensed vaccines has significantly declined because of reformulations and the availability of vaccines in single-dose containers. Currently, a couple of flu vaccines are formulated to contain thimerosal, although the majority of flu vaccines that currently exist do not contain thimerosal. The ACIP will convene later this week to hold a vote on the status of thimerosal on vaccines. Even if completely removed from the flu vaccine, the vaccine will not 'become' safer, as decades of research has already shown thimerosal to be safe and effective as a preservative. Experts warn that holding the vote could cast doubt on vaccine uptake. Dr. Jeremy Faust, Editor-in-Chief of MedPage Today, writes, 'Elevating this debunked myth to national policy lends credence to misinformation, and sets the stage for other actions that may undermine vaccine confidence in the United States.'
